Literature DB >> 22307870

Effect of obesity and glycemic control on serum lipocalins and insulin-like growth factor axis in type 2 diabetic patients.

Hala O El-Mesallamy1, Nadia M Hamdy, Al-aliaa M Sallam.   

Abstract

Obesity, insulin resistance (IR), and progressive decline in pancreatic β-cell function are major features of type 2 diabetes mellitus (T2DM). Altered adipokines contribute to obesity-induced IR. Hence understanding of adipokines' relation to obesity and glycemic control could be useful to improve disease outcomes. We aimed at determination of serum retinol binding protein-4 (RBP-4), lipocalin-2 (LCN-2), insulin-like growth factor-I (IGF-I), and its binding protein-3 (IGFBP-3) levels in T2DM patients with the impact of obesity and glycemic control on them and their relation to β-cell function. Serum insulin, RBP-4, LCN-2, IGF-I, and IGFBP-3 estimated by ELISA were examined in 32 T2DM patients and age- and sex-matched 20 healthy controls. Significant elevation was observed in serum RBP-4 (P < 0.001), LCN-2 (P < 0.01), and IGF-I/IGFBP-3 molar ratio (P < 0.05) in T2DM patients in comparison with healthy controls. There was no significant difference in them between nonobese and obese diabetics. However, RBP-4 and IGF/IGFBP-3 molar ratio were higher in uncontrolled than in controlled diabetic patients at P < 0.001 and P < 0.01, respectively. Moreover, RBP-4, LCN-2, and IGF-I/IGFBP-3 molar ratio were negatively correlated with β-cell function. In conclusion, serum RBP-4 and IGF-I/IGFBP-3 molar ratio but not LCN-2 were prominently elevated with poor glycemic control rather than obesity in T2DM patients. Whereas, declining β-cell function is associated with elevation of serum RBP-4, LCN-2 as well as IGF-I/IGFBP-3 molar ratio.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22307870     DOI: 10.1007/s00592-012-0373-6

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  5 in total

Review 1.  Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer.

Authors:  Phil A Hart; Melena D Bellin; Dana K Andersen; David Bradley; Zobeida Cruz-Monserrate; Christopher E Forsmark; Mark O Goodarzi; Aida Habtezion; Murray Korc; Yogish C Kudva; Stephen J Pandol; Dhiraj Yadav; Suresh T Chari
Journal:  Lancet Gastroenterol Hepatol       Date:  2016-10-12

2.  Insulin-like growth factor I, growth hormone, and insulin sensitivity: the effects of a one-year cholecalciferol supplementation in middle-aged overweight and obese subjects.

Authors:  Elena Kamycheva; Vivian Berg; Rolf Jorde
Journal:  Endocrine       Date:  2012-10-30       Impact factor: 3.633

3.  Lipocalin-2: a role in hepatic gluconeogenesis via AMP-activated protein kinase (AMPK).

Authors:  W-X Sun; K Lou; L-J Chen; S-D Liu; S-G Pang
Journal:  J Endocrinol Invest       Date:  2021-01-09       Impact factor: 4.256

4.  Association of lipocalin-2 level, glycemic status and obesity in type 2 diabetes mellitus.

Authors:  Areej E Elkhidir; Halima B Eltaher; Abdelrahim O Mohamed
Journal:  BMC Res Notes       Date:  2017-07-14

Review 5.  Lipocalin 2 Participates in the Epidermal Differentiation and Inflammatory Processes of Psoriasis.

Authors:  Kaixuan Ren; Yumin Xia
Journal:  J Inflamm Res       Date:  2022-03-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.